Peroxisome proliferator-activated receptors (PPARS) and their implications in diseases

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 1, 2000, Pages 8-18

  Vamecq, Joseph ^a,d   Latruffe, Norbert ^b,c  

^a INSERM   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DIABETES MELLITUS; DYSLIPIDEMIA; HYPERTENSION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; MALIGNANT NEOPLASTIC DISEASE; OBESITY; PATHOGENESIS; PROTEIN FAMILY; PROTEIN LOCALIZATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 0034007494     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200002000-00002     Document Type: Article

References (83)

1. 1 Desvergne B, Wahli W: PPAR: a key nuclear factor in nutrient/gene interactions? In: Inducible gene expression. Edited by Bauerie PA. Boston: Birkhauser, 1995 (Vol 1):142-176.
2. 2 Gelman L, Fruchart JC, Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999, 55:932-943. Overview of the molecular biologic aspects of the interactions of PPARs with transcriptional factors and cofactors.
3. 3 Lemberger T, Desvergne B, Wahli W: Peroxisome proliferators-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996, 2:335-363.
4. 4 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al.: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
5. 5 Shao D, Rangwala SM, Bailley ST, Krakow SL, Reginato MJ, Lazar MA: Interdomain communication regulating ligand binding by PPAR-γ. Nature 1998, 396:377-380. A good characterization of the ligand-independant transactivation domain of PPARγ.
6. 6 Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CA: Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 1999, 274:10505-10510. A decisive advance in the mechanisms governing ligand-independent transactivation mechanisms of PPARα.
7. 7 Passily P, Schohn H, Jannin B, Malki MC, Boscoboinik D, Dauça M, Latruffe N: Phosphorylation of peroxisome proliferator-activated receptor α in rat Fao cells and stimulation by ciprofibrate. Biochem Pharmacol 1999, 58:1001-1008.
8. 8 Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B: The nuclear receptors peroxisome proliferator-activated receptor α and rev-erbα mediate the species-specific regulation of apolipoprotein 1-I expression by fibrates. J Biol Chem 1998, 273:25713-25720.
9. 9 Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B: Fibrates increase human REV-ERBa expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol 1999, 13:400-409. Demonstration that PPREs may obey a DR2 pattern (in addition to previously documented DR1 patterns for these responsive elements).
10. 10 Tu AY, Albers JJ: DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate. Biochem Biophys Res Commun 1999, 264:802-807. Direct down-regulatory properties of PPARs through PPRE (PPAR/PPRE interactions being classically considered as having up-regulatory properties on gene expression).
11. 11 Stephens JM, Morrison RF, Wu Z, Farmer SR: PPARγ ligand-dependent induction of STAT1, STAT5A and STAT5B during adipogenesis. Biochem Biophys Res Commun 1999, 262:216-222. A good example of interactions between PPAR and STAT pathways.
12. 12 Zhou YC, Waxman DJ: STAT5b down-regulates peroxisome proliferator-activated receptor α transcription by inhibition of ligand-independent activation function region-1 trans-activation domain. J Biol Chem 1999, 274:29874-29882. A important example of interactions between PPAR and STAT pathways.
13. 13 Zhou YC, Waxman DJ: Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARα) signaling pathways. Growth hormone inhibition of PPARα transcriptional activity mediated by stat5b. J Biol Chem 1999, 274:2672-2681. Experimental work pointing out growth hormone-mediated effects occurring through cross-talk between PPARs and STAT pathways.
14. 14 Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
15. 15 Ellinghaus P, Wolfrum C, Assmann G, Spener F, Seedorf U: Phytanic acid activates the peroxisome proliferator-activated receptor α (PPARα) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice. J Biol Chem 1999, 274:2766-2772.
16. 16 Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RA: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998, 93:229-240.
17. 17 Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RA: PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 1998, 93:241-252. Two important experimental works illustrating the effects of PPARγ activation (ie, foam cell formation) in atherosclerosis.
18. 18 Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, et al.: N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998, 41:5020-5036.
19. 19 Collins JL, Blanchard SG, Boswell EG, Charifson PS, Cobb JE, Henke BR, et al.: N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimalization of the phenyl alkyl ether moiety. J Med Chem 1998, 41:5037-5054.
20. 20 Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, et al.: N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 3. Structure-activity relationship and optimalization of the N-aryl substituent. J Med Chem 1998, 41:5055-5069.
21. 21 Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, et al.: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48:1415-1424.
22. 22 Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, et al.: Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J Biol Chem 1999, 274:6718-6725.
23. 23 Haigh D, Allen G, Birrell HC, et al.: Non-thiazolidinedione antihyperglycaemic agents. Part 3: The effects of stereochemistry on the potency of α-methyl-β-phenylpropanoic acids. Bioorg Med Chem 1999, 7:821-830.
24. 24 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270:12953-12956.
25. 25 Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999, 16:179-192. Review of the biologic effects and indications in diabetes for a class of drugs that are ligands of PPARγ.
26. 26 Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-acttivated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
27. 27 Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, et al.: A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999, 96:6102-6106. A good experimental work for the design of PPARγ-weak agonists with PPARγ antagonizing properties and the role of an α-helix in PPAR and other protein interactions.
28. 28 Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β and-γ in the adult rat. Endocrinology 1996, 137:354-366.
29. 29 Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354(9173):141-148. Review of the medical significance of PPARs.
30. 30 Issemann I, Green S: Activation of a member of the steroid receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
31. 31 Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J, Wilkinson C, et al.: A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol 1999, 29:327-357. This work contributes to invalidation in humans of the role of PPARα ligands in hepatocarcinogenesis (in contrast with rodents)
32. 32 Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al.: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999, 85:394-402.
33. 33 Fruchart JC, Duriez P, Staels B: Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10:245-257. A good review for recent advance in therapeutic benefit of PPARα ligand fibrates in cardiovascular disorders.
34. 34 Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999, 19:2094-2104.
35. 35 Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
36. 36 Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Tora I, et al.: Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature 1998, 393:790-793.
37. 37 Zhu L, Bisgaier CL, Avriram M, Newton RS: 9-Cis retinoic acid induces monocyte, chemoattractant protein-1 secretion in human monocylic THP-1 cells. Arterioscler Thromb Vasc Biol 1999, 19:2105-2111.
38. 38 Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia 1999, 42:1033-1049. An excellent review of the extraordinary breakthrough of PPARγ in physiology and pathogenesis, with expert consideration of underlying molecular biology mechanisms.
39. 39 Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87:377-389.
40. 40 Auboeuf D, Rieusset J, Fajas L, Vallier P, Freering V, Riou JP, et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans:n No alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
41. 41 Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, et al.: Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-γ in human adipocytes. Diabetes 1999, 48:699-705. Experimental work indicating that insulin up-regulates PPARγ expression in human adipose tissue.
42. 42 Vidal-Puig A, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin abd glucocorticoids. J Clin Invest 1997, 99:2416-2422.
43. 43 Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, et al.: Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells. Proc Natl Acad Sci USA 1998, 95:8898-8903.
44. 44 Kwon G, Xu G, Marshall CA, McDaniel ML: Tumor necrosis factor α-induced pancreatic β-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Δ12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor γ activation and inos expression. J Biol Chem 1999, 274:18702-18708.
45. 45 Auwerx J, Staels B: Leptin. Lancet 1998, 351:737-742.
46. 46 Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, Kobayashi K: Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 1999, 44:107-114.
47. 47 Pershadsingh HA: Pharmacological peroxisome proliferator-activated receptor γ ligands: emerging clinical indications beyond diabetes. Exp Opin Invest Drugs 1999, 8:1859-1872. An excellent review of the biologic effects of thiazolidinediones, and their current and possibly future indications in diseases other than diabetes.
48. 48 Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998, 339:959-959. A unique opportunity to assess the pathophysiologic relevance of the phosphorylation site of PPARγ in the development of diabetes and obesity.
49. 49 Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O: Homozygosity of the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma 2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999, 42:892-895.
50. 50 Hamann A, Munzberg H, Buttron P, Busing B, Hinney A, Mayer H, et al.: Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects. Eur J Endocrinol 1999, 141:90-92.
51. 51 Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkhanen L, Kuusisto J, et al.: A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
52. 52 Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V; Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999, 48:1466-1468.
53. 53 Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, et al.: The PPARγ2 amino acid polymorphism Pro12Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999, 42:758-762.
54. 54 Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, et al.: Two polymorphisms in the peroxisome proliferator-activated receptor γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999, 84:3708-3712.
55. 55 Meirhaege A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, et al.: A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998, 7:435-440.
56. 56 Thournalley PJ: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998, 44:1013-1023.
57. 57 Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998, 37:586-600.
58. 58 Basta G, De Caterina R: Products of advanced glycosylation and the pathogenesis of accelerated atherosclerosis in diabetes. G Ital Cardiol 1996, 26:699-719.
59. 59 Ruggiero D, Lecomte M, Michoud E, Lagarde M, Wiernsperger N: Involvement of cell-cell interactions in the pathogenesis of diabetic retinopathy. Diabetes Nutr 1997, 23:30-42.
60. 60 Iwashima Y, Eto M, Horiuchi S, Sano H: Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. Biochem Biophys Res Commun 1999, 264:441-448. An important finding in the medically relevant relationships and interactions between advanced glycation end-products (AGEs) and PPARs.
61. 61 Kurtz TW, Gardner DG: Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 1998, 32:380-386. An excellent review of modulation of gene transcription as a strategy for treating hypertension.
62. 62 Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999, 274:9116-9121. Experimental work with important consequences for PPARγ in diseases affecting angiogenesis.
63. 63 Roos R: Atherosclerosis: an inflammatory disease. New Engl J Med 1999, 340:115-126. Excellent expert review on the concept of atherosclerosis and multi-stage events of this inflammatory disease.
64. 64 Chen NG, Sarabia SF, Malloy PJ, Zhao XY, Feldman D, Reaven GM: PPARγ agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. Biochem Biophys Res Commun 1999, 263:718-722.
65. 65 Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al.: Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial function. Biochem Biophys Res Commun 1999, 258:431-435.
66. 66 Olsson U, Bondjers G, Camejo G: Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 1999, 48:616-622.
67. 67 Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al.: Expression of the peroxisome proliferator activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci US 1998, 95:7614-7619. An excellent account of the undesirable effects of PPARγ in atherosclerosis.
68. 68 Bishop-Bailey D, Hla T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 1999, 274:17042-17048.
69. 69 Goetze S, Xi Xp, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE: PPARg ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999, 33:798-806.
70. 70 Corton JC, Fan LQ, Brown S, Anderson SP, Bocos C, Cattley RC, et al.: Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol Pharmacol 1998, 54:463-473.
71. 71 Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Tora I, et al.: Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature 1998, 393:790-793.
72. 72 Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17-23. An excellent experimental work with important medical relevance regarding the potentially beneficial effect of PPARγ agonists in plaque rupture, a late complication in atherosclerosis.
73. 73 Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N, Koeffler HP: Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator-activated receptor γ, and retinoids. Int J Oncol 1999, 15:1027-1031. Preliminary evidence for the activity of PPARγ agonist against myeloid leukemia.
74. 74 Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD: 15-Deoxy-delta (12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor γ, induces apopoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 1999, 262:579-585.
75. 75 Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999, 455:135-139. Good experimental work in showing that apoptosis, like cell differentiation, contributes to the anti-cancerous activity of PPARγ, here, against gastric tumoral cell growth.
76. 76 Vamecq J, Latruffe N: Are physiological expansion and maturation pathways a basis for discrepant behaviour of colon tumoral cell growth in response to the thiazolidinedione PPARγ agonists? Oncol Rep 1999, 6:1281-1283.
77. 77 Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, et al.: Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999, 3:799-804. Work indicating occurrence of truncated forms of PPARs in tumoral cells.
78. 78 Rivier M, Safonova I, Griffiths CEM, Ailhaud G, Micher S: Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Clin Dermatol 1998, 111:1116-1121.
79. 79 Baert FJ, Rutgeerts PR: Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999, 14:47-51.
80. 80 Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al.: A novel therapy for colitis utilizing PPARg ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999, 104:383-389. Experimental evidence for PPARγ-mediated improvement of large bowell inflammatory states.
81. 81 Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H, et al.: Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999, 117:73-81. Experimental evidence for PPARγ-mediated cell events taking place in large bowel inflammatory states.
82. 82 Fearon U, Reece R, Smith J, Emery P, Veale DJ: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in eraly rheumatoid and psoriatic arthritis patients. Ann NY Acad Sci 1999, 878:619-821.
83. 83 Wiesenberg I, Chiesi M, Missbach M, Spanka C, Pignat W, Carlberg C: Specific activation of the nuclear receptors PPARg and RORA by the antidiabetic thiazolidinedione BRL49653b and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol 1998, 53:1131-1138.